Herantis Pharma Oyj (HRTIS) - Cash Flow Conversion Efficiency

Latest as of June 2025: -1.937x

Based on the latest financial reports, Herantis Pharma Oyj (HRTIS) has a cash flow conversion efficiency ratio of -1.937x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.39 Million ≈ $-3.96 Million USD) by net assets (€1.75 Million ≈ $2.04 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Herantis Pharma Oyj (HRTIS) balance sheet quality index to measure how much of total assets are equity-financed.

Herantis Pharma Oyj - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how Herantis Pharma Oyj's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Herantis Pharma Oyj cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

Herantis Pharma Oyj Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Herantis Pharma Oyj ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
EgnsINVEST Ejendomme Tyskland A/S CO:EGNETY	0.003x
Nam Kwang Cons KO:001260	-0.101x
Sonel S.A. WAR:SON	-0.006x
Y/KNOT S.A. AT:YKNOT	N/A
Evrofarma SA AT:EVROF	-0.018x
Experience Co Ltd AU:EXP	0.044x
York Timber Holdings Ltd JSE:YRK	0.024x
Ozerden Plastik Sanayi IS:OZRDN	0.718x

Annual Cash Flow Conversion Efficiency for Herantis Pharma Oyj (2012–2024)

The table below shows the annual cash flow conversion efficiency of Herantis Pharma Oyj from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Herantis Pharma Oyj.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€-243.00K ≈ $-284.09K	€-6.54 Million ≈ $-7.65 Million	26.934x	+2845.91%
2023-12-31	€4.73 Million ≈ $5.53 Million	€-4.64 Million ≈ $-5.42 Million	-0.981x	-100.66%
2022-12-31	€-60.28K ≈ $-70.48K	€-8.94 Million ≈ $-10.46 Million	148.365x	+927.89%
2021-12-31	€554.30K ≈ $648.04K	€-9.93 Million ≈ $-11.61 Million	-17.921x	-1488.32%
2020-12-31	€7.59 Million ≈ $8.87 Million	€-8.56 Million ≈ $-10.01 Million	-1.128x	+64.95%
2019-12-31	€1.85 Million ≈ $2.16 Million	€-5.96 Million ≈ $-6.97 Million	-3.219x	-107.70%
2018-12-31	€-89.29K ≈ $-104.39K	€-3.73 Million ≈ $-4.36 Million	41.801x	+6678.70%
2017-12-31	€4.09 Million ≈ $4.78 Million	€-2.60 Million ≈ $-3.04 Million	-0.635x	+67.04%
2016-12-31	€1.57 Million ≈ $1.84 Million	€-3.04 Million ≈ $-3.55 Million	-1.928x	-56.32%
2015-12-31	€6.00 Million ≈ $7.01 Million	€-7.40 Million ≈ $-8.65 Million	-1.233x	-514.33%
2014-12-31	€21.72 Million ≈ $25.39 Million	€-4.36 Million ≈ $-5.10 Million	-0.201x	+89.26%
2013-12-31	€120.00K ≈ $140.29K	€-224.21K ≈ $-262.13K	-1.868x	-101.18%
2012-12-31	€-3.37K ≈ $-3.94K	€-533.42K ≈ $-623.62K	158.097x	--

About Herantis Pharma Oyj

HE:HRTIS Finland Biotechnology

Market Cap

$52.37 Million

€44.79 Million EUR

Market Cap Rank

#21697 Global

#108 in Finland

Share Price

€1.69

Change (1 day)

-1.05%

52-Week Range

€1.58 - €2.78

All Time High

€10.10